C3M

1. Ras inhibitors + GLP-1 receptor agonists increase C3M in humans.

   “Combination therapy (RASi + GLP-1 RA) was associated with higher urinary C3M levels compared with RASi monotherapy (P = 0.036).”

   Humanspeople with T2D

   Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes

   American journal of physiology. Cell physiology·17 Aug 2026

More on Ras inhibitors + GLP-1 receptor agonists